Abiopharma

🔍 Aghili Aziz (Director)

Company: COLUMBUS MCKINNON CORP (CMCO)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | shares_owned_after: 19,536.08
• Acquired 3,617 shares of Deferred Stock (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,629.85 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3
• Acquired 8,705 shares of Deferred Stock (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,737.14 | transaction_form_type: 4 | Footnotes: F1, F2, F4, F4
• Acquired 7,590 shares of Deferred Stock (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,590.00 | transaction_form_type: 4 | Footnotes: F1, F5, F4, F4

Footnotes:

• F1: Each deferred stock unit is equal in value to one share of Columbus McKinnon Corporation common stock.
• F2: Represents additional deferred stock units attributable to dividend reinvestment.
• F3: Deferred Shares will be delivered to the reporting person on January 1, 2027, under and subject to the terms of the Columbus McKinnon Corporation 2016 Long Term Incentive Plan as amended and restated effective June 4, 2024, and further amended effective August 14, 2026.
• F4: Deferred Shares will be delivered to the reporting person upon separation, under and subject to the terms of the Columbus McKinnon Corporation 2016 Long Term Incentive Plan as amended and restated effective June 4, 2024, and further amended effective August 14, 2026.
• F5: Represents deferred stock units issued to reporting person under the Columbus McKinnon Corporation 2016 Long Term Incentive Plan as amended and restated effective June 4, 2024, and further amended effective August 14, 2026.